This is an old revision of the document!
McGill Interdisciplinary Initiative in Infection and Immunity
The McGill Interdisciplinary Initiative in Infection and Immunity (MI4) is a Canadian research organization in Montreal, Quebec. It is based out of McGill University.
History
COVID-19
MI4 provided research funding related to COVID-19 through their “MI4 Emergency COVID-19 Research Funding” program.1) In particular, MI4 participated as a funding partner of the Canadian arm of the first randomized control trial (RCT) testing hydroxychloroquine for the post-exposure prevention of COVID-19, led by principal investigator David Boulware, which began on March 17, 2020.2)
Organization
Partners
MI4's partners within McGill include:3)
- Advanced BioImaging Facility (ABIF)
Funding
MI4 received funding for their “MI4 Emergency COVID-19 Research Funding” program through the McGill University Health Centre Foundation COVID-19 Emergency Fund from:4)
Activities
| MI4 Emergency COVID-19 Research Funding5) | |
|---|---|
| MI4 ECRF Round 2 | |
| Lead investigators | Project title |
| Nicole Basta | Real-Time Tracking of COVID-19 Vaccine Development |
| Inés Colmegna, Amal Bessissow, David Meger | Use of Technology to Improve Effects of Social Isolation on Hospitalized COVID-19 Patients (TIES-COVID) |
| Gonzalo Cosa | Novel Small Molecule Antiviral Agents for Treatment of SARS-CoV-2 causing COVID 19 coronavirus disease: Target Identification and Structural Optimization |
